Companies › Lepu Biopharma
4 active drug programs in 37 registered trials: 24 Phase 2, 8 Phase 1, 5 Phase 3; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MRG003 TIGIT inhibitor | – | Phase 3 | Squamous Cell Carcinoma of the Head and Neck; Recurrent or Metastatic Nasopharyngeal Carcinoma; Advanced Solid Tumors | Dec 2026 |
| Pucotenlimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Recurrent or Metastatic Nasopharyngeal Carcinoma; Head and Neck Squamous Cell Carcinoma; Advanced Solid Tumors; Hepatocellular Carcinoma … | Aug 2027 |
| Becotatug Vedotin for Injection Anti-TROP-2 antibody-drug conjugate | TACSTD2 | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2027 |
| MRG006A uncertain mechanism | – | Phase 1 | Advanced Solid Tumors; Hepatocellular Carcinoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07312422 | Pucotenlimab | Phase 1 | Pancreatic Cancer | Oncology | Apr 2026 |
| NCT06524466 | Pucotenlimab | Phase 2 | Resectable Hepatocellular Carcinoma | Oncology | Dec 2026 |
| NCT06456892 | Pucotenlimab | Phase 1 | Rhabdomyosarcoma | Oncology | Dec 2026 |
| NCT05126719 | MRG003 | Phase 2 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Oncology | Dec 2026 |
| NCT07386158 | Pucotenlimab | Phase 2 | Vorolanib | Oncology | Dec 2026 |
| NCT07814287 | Pucotenlimab | Phase 2 | Head and Neck Squamous Cell Carcinoma, HNSCC | Oncology | Dec 2026 |
| NCT07105852 | Pucotenlimab | Phase 2 | Cholangiocarcinoma | Oncology | Jul 2027 |
| NCT05688605 | MRG003 | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT05688605 | Pucotenlimab | Phase 1 | Advanced Solid Tumors | Oncology | Aug 2027 |
| NCT07448142 | Pucotenlimab | Phase 2 | Colorectal Cancer (CRC) | Oncology | Sep 2027 |
| NCT07665190 | Pucotenlimab | Phase 2 | Hypopharyngeal Squamous Cell Carcinoma | Oncology | Oct 2027 |
| NCT07665190 | Pucotenlimab | Phase 2 | Hypopharyngeal Squamous Cell Carcinoma | Oncology | Oct 2027 |
| NCT05751512 | MRG003 | Phase 3 | Squamous Cell Carcinoma of the Head and Neck | Oncology | Dec 2027 |
| NCT07586124 | Pucotenlimab | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2027 |
| NCT07586124 | Becotatug Vedotin for Injection | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Dec 2027 |
| NCT07093970 | MRG006A | Phase 1 | Advanced Solid Tumors | Oncology | Dec 2027 |
| NCT06969534 | Pucotenlimab | Phase 2 | Lymphoepithelioma-like Carcinoma | Oncology | Dec 2027 |
| NCT06889610 | Pucotenlimab | Phase 2 | Triple Negative Breast Cancer Metastatic | Oncology | Dec 2027 |
| NCT06770270 | Pucotenlimab | Phase 2 | Rectal Cancer | Oncology | Dec 2027 |
| NCT07479485 | Pucotenlimab | Phase 1 | Hepatocellular Carcinoma | Oncology | Apr 2028 |
| NCT07479485 | MRG006A | Phase 1 | Hepatocellular Carcinoma | Oncology | Apr 2028 |
| NCT07518979 | Pucotenlimab | Phase 2 | Penile Cancer | Oncology | May 2028 |
| NCT07464366 | Pucotenlimab | Phase 2 | Salivary Gland Carcinomas | Oncology | May 2028 |
| NCT07632339 | Pucotenlimab | Phase 2 | Head and Neck Cancer | Oncology | Jun 2028 |
| NCT06192797 | Pucotenlimab | Phase 2 | Cholangiocarcinoma Non-resectable | Oncology | Jun 2028 |
| NCT07712029 | Pucotenlimab | Phase 2 | Advanced Refractory Solid Tumors | Oncology | Aug 2028 |
| NCT07896668 | Pucotenlimab | Phase 2 | Breast Cancer | Oncology | Sep 2028 |
| NCT07884188 | Pucotenlimab | Phase 2 | Metastatic Colorectal Cancer | Oncology | Oct 2028 |
| NCT07235566 | Pucotenlimab | Phase 2 | Thyroid Cancer | Oncology | Apr 2029 |
| NCT07497919 | Pucotenlimab | Phase 2 | Penile Cancer | Oncology | May 2029 |
| NCT06976190 | MRG003 | Phase 3 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Oncology | May 2029 |
| NCT06976190 | Pucotenlimab | Phase 3 | Recurrent or Metastatic Nasopharyngeal Carcinoma | Oncology | May 2029 |
| NCT06959108 | Pucotenlimab | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Oncology | Jun 2029 |
| NCT07750067 | Pucotenlimab | Phase 2 | Melanoma Metastatic | Oncology | Jul 2030 |
| NCT07054307 | Pucotenlimab | Phase 1 | Penile Cancer | Oncology | Jul 2030 |
| NCT07524452 | Pucotenlimab | Phase 3 | Locally Advanced Head and Neck Squamous Cell Carcinoma | Oncology | Feb 2031 |
| NCT07528209 | Pucotenlimab | Phase 3 | Rectal Cancer | Oncology | Apr 2032 |
Innovent Biopharmaceutical Technology (Hangzhou) BeiGene mAbxience Research Genfleet Therapeutics (Shanghai) Klus Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.